Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria del Hospital Universitario La Paz (65)

2024

  1. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

    Journal of Clinical Oncology

  2. Incidence of Diabetes Mellitus and Associated Factors in the Era of Antiretroviral Drugs With a Low Metabolic Toxicity Profile

    Open Forum Infectious Diseases, Vol. 11, Núm. 4

  3. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Annals of Oncology, Vol. 35, Núm. 11, pp. 981-992

  4. Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer–a plain language summary

    Future Oncology, Vol. 20, Núm. 22, pp. 1531-1544

  5. Sleep apnoea increases biomarkers of immune evasion, lymphangiogenesis and tumour cell aggressiveness in high-risk patients and those with established lung cancer

    ERJ Open Research, Vol. 10, Núm. 1

  6. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

    Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284

  7. Ulnar Distribution Pattern May Be Predominant in Upper Extremity Lymphatic Malformations

    Indian Journal of Surgery, Vol. 86, Núm. 4, pp. 756-759

2023

  1. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

    Science advances, Vol. 9, Núm. 33, pp. eadf6692

  2. Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: A stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 929-936

  3. Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus

    Journal of gynecologic oncology, Vol. 34, Núm. 5, pp. e57

  4. Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3519-3526

  5. Low Plasma Levels of Hyaluronic Acid Might Rule Out Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation

    Disease Markers, Vol. 2023

  6. Prevention of Alzheimer’s Disease and Cognitive Decline with Diet & Lifestyle: Proceedings of the A. G. Leventis Foundation Conference

    Journal of Prevention of Alzheimer's Disease, Vol. 10, Núm. 1, pp. 137-143

  7. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

    European Journal of Cancer, Vol. 189

  8. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

    Genome Medicine, Vol. 15, Núm. 1

  9. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

    Journal of Clinical Medicine, Vol. 12, Núm. 20

  10. Treosulfan-Based Conditioning Regimen In Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Analysis on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)

    Transplantation and Cellular Therapy, Vol. 29, Núm. 11, pp. 702.e1-702.e11

2022

  1. Abdominal normothermic regional perfusion in controlled donation after circulatory determination of death liver transplantation: Outcomes and risk factors for graft loss

    American Journal of Transplantation, Vol. 22, Núm. 4, pp. 1169-1181

  2. Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models

    Frontiers in Oncology, Vol. 12

  3. Case Report: The Value of Genomic Analysis in a Case of Megakaryoblastic Leukemia With Atypical Initial Manifestation

    Frontiers in Pediatrics, Vol. 10